Adoption of novel oral targeted therapies for treatment of chronic lymphocytic leukemia (CLL) could raise the treatment costs for the blood-system cancer in the U.S. by almost 600 percent. In their analysis in the Journal ...
Nov 21, 2016
0
0
A previously unknown safety mechanism in our immune system keeps the body free from autoimmune diseases. Researchers from Karolinska Institutet have discovered that a cell in our inherited immune system can prevent our adaptive ...
Nov 1, 2016
0
35
Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.
Oct 24, 2016
0
0
Early testing of a new drug combination that attacks the most common form of leukaemia on multiple fronts has shown great promise in targeting cancer cells.
Oct 17, 2016
0
1
Leukemia is a disease in which each cell can exhibit different genetic traits, and now Swedish researchers have found a cheap way to examine the individual cells. Reported in Nature Communications, the breakthrough could ...
Oct 14, 2016
0
1
Ibrutinib was approved in 2014 for the treatment of certain adults with chronic lymphocytic leukaemia (CLL), particularly as second-line treatment. The therapeutic indication was expanded in 2016. The drug is now also approved ...
Oct 11, 2016
0
0
Since the day they came home from the hospital in matching newborn monkey outfits, Zane and Zac Taylor have done everything together.
Sep 23, 2016
0
3
In a study published online this week in Science Translational Medicine, investigators from Brigham and Women's Hospital and the Santa Lucia Foundation in Rome report that resolvins and maresins, molecules produced in the ...
Aug 24, 2016
0
354
Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with ...
Jul 6, 2016
0
0
Treating B cell malignancies with the patients' own T cells modified so as to target specific B cell markers has shown clinical success.
Jun 6, 2016
0
1
